TITLE

Chemoradiotherapy: The New Standard Care for Invasive Cervical Cancer

AUTHOR(S)
Rose, P.G.
PUB. DATE
December 2000
SOURCE
Drugs;Dec2000, Vol. 60 Issue 6, p1239
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cervical cancer remains a major health problem worldwide, despite advances in screening. For patients with locally advanced stage disease, failure to obtain local-regional control usually results in death. In an effort to improve local-regional tumour control, neoadjuvant and concurrent chemoradiation have been tested. Recently, 5 randomised trials performed by the Gynecologic Oncology Group, Radiation Therapy Oncology Group and the Southwest Oncology Group studying cisplatin-based chemoradiation have demonstrated a significant survival advantage. Three of the trials compared cisplatin-based concurrent chemotherapy and radiation to radiation alone and 2 trials compared cisplatin-based concurrent chemotherapy and radiation to radiation with hydroxyurea. In all trials, cisplatin-based chemotherapy administered concurrently with radiation therapy was the more effective therapy, reducing the risk of death by 30 to 50%. Acute toxicities, principally neutropenia and gastrointestinal, were more common with chemoradiation but were transient and rates of late complications were similar between treatment groups. Based on the results of these 5 randomised trials, the National Cancer Institute released a Clinical Announcement stating that cisplatin-based chemotherapy as used in these trials concurrently with radiation therapy should be the new standard of therapy for high risk early stage and locally advanced stage cervical cancer.
ACCESSION #
9592884

 

Related Articles

  • Evidence supports chemoradiation for cervical cancer. Lucas, Beverly D.; Botha, Rosanne // Patient Care;4/30/1999, Vol. 33 Issue 8, p9 

    Reports on evidences supporting the use of chemoradiation for the treatment of cervical cancer. Improved survival rates of patients treated with chemotherapy and radiation therapy; Relative risk estimate of patients treated with chemoradiation; Impact of disease stage and dose of radiation on...

  • Prognostic Impact of Carcinoembryonic Angtigen (CEA) in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy. Shibata, Kiyosumi; Kajiyama, Hiroaki; Mizuno, Mik; Yamamoto, Eiko; Kikkawa, Fumitaka // Surgical Science;Oct2012, Vol. 3 Issue 10, p463 

    Objective: To identify prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT). Methods and Materials: We analyzed 76 patients with FIGO stage IB2-IVb cervical cancer treated with CCRT between 2001 and 2006 at the Nagoya University...

  • Radical radiotherapy treatment (EBRT + HDR-ICRT) of carcinoma of the uterine cervix: Outcome in patients treated at a rural center in India. Jain, Vandana S.; Singh, Kailash K.; Shrivastava, Rajeev; Saumsundaram, K. V.; Sarje, Mukund B.; Jain, Shailendra M. // Journal of Cancer Research & Therapeutics;Oct-Dec2007, Vol. 3 Issue 4, p211 

    Aim: To report the outcome of carcinoma of the uterine cervix patients treated radically by external beam radiotherapy (EBRT) and high-dose-rate (HDR) intracavitary radiotherapy (ICRT). Materials and Methods: Between January 1997 to December 2001, a total of 550 newly diagnosed cases of...

  • A One-Two vs. Cancer. Kalb, Claudia // Bulletin with Newsweek;03/09/99, Vol. 117 Issue 6164, p66 

    States that the United States National Cancer Institute announced a treatment for cervical cancer that increases the chance of survival. Reduction of mortality with chemoradiation; Brief details of the study by Mitchell Morris et al at Houston's M.D. Anderson Cancer Center in Texas.

  • A One-Two vs. Cancer. Kalb, Claudia // Newsweek (Pacific Edition);03/08/99 (Pacific Edition), Vol. 133 Issue 10, p55 

    States that the United States National Cancer Institute announced a treatment for cervical cancer that increases the chance of survival. Reduction of mortality with chemoradiation; Brief details of the study by Mitchell Morris et al at Houston's M.D. Anderson Cancer Center in Texas.

  • A One-Two vs. Cancer. Kalb, Claudia // Newsweek (Atlantic Edition);03/08/99 (Atlantic Edition), Vol. 133 Issue 10, p63 

    States that the United States National Cancer Institute announced a treatment for cervical cancer that increases the chance of survival. Reduction of mortality with chemoradiation; Brief details of the study by Mitchell Morris et al at Houston's M.D. Anderson Cancer Center in Texas.

  • A One-Two vs. Cancer. Kalb, Claudia // Newsweek;3/8/1999, Vol. 133 Issue 10, p28 

    States that the United States National Cancer Institute announced a treatment for cervical cancer that increases the chance of survival. Reduction of mortality with chemoradiation; Brief details of the study by Mitchell Morris et al at Houston's M.D. Anderson Cancer Center in Texas.

  • Role of Chemoradiation in Advanced Cervical Cancer. Singh, T.T.; Singh, I.Y.; Sharma, D.T.; Singh, N.R.K. // Indian Journal of Cancer;Jul2003, Vol. 40 Issue 3, p101 

    A prospective randomized study was conducted in our department of Radiotherapy, Regional Institute of Medical Sciences, Imphal to evaluating the role of chemoradiation in the management of advanced inoperable cervical cancer (stage IIB-IIIB) taking only radiation treatment as control spanning...

  • Concurrent Chemoradiation for Cervical Cancer: Results of Five Randomized Trials.  // Medical Archives / Medicinski Arhiv;2010, Vol. 64 Issue 6, p368 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics